AAGH · America Great Health
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.”View the 10-Q filed Aug 6, 2026
2 customers — 22% of revenue (nine months ended March 31, 2026)
“For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period.”
One customer — 22% of revenue (nine months ended March 31, 2026)
“For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period.”
One customer — 13% of revenue (three months ended March 31, 2026)
“For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period.”
2 customers — 10% of revenue (three months ended March 31, 2026)
“For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period.”
One customer — 11% of revenue (nine months ended March 31, 2025)
“For the nine months ended March 31, 2025, only one major customer accounted for approximately 11% of our total revenue during the period.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AAGH
this stock
America Great Health
|
$12.72M | +500.0% | +32.9% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AAGH | +100.0% | +100.0% | +50.0% | +200.0% | +500.0% |
| SPY | -0.1% | +2.7% | +9.4% | +2.0% | +14.1% |
| vs SPY | +100.1% | +97.3% | +40.6% | +198.0% | +485.9% |